Source: Annual Congress 2011 - Respiratory epidemiology: genetics and modifiable risk factors
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
E. van de Garde, S. Meijvis, M. C. Cornips, P. Voorn, P. Souverein, H. Endeman, D. Biesma, H. Leufkens (Nieuwegein, Utrecht, Amsterdam, Netherlands). Microbial evaluation of proton pump inhibitors and the risk of pneumonia. Eur Respir J 2011; 38: Suppl. 55, 1012

Member's Comments

No comment yet.

Related content which might interest you: Microbial evaluation of proton-pump inhibitors and the risk of pneumonia Source: Eur Respir J 2011; 38: 1165-1172 Year: 2011 The risk of community-acquired pneumonia and the use of statins, ACE inhibitors and gastric acid suppressants Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008 A systematic review of the efficacy of proton pump inhibitors on refractory adult asthma. Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Predicting intrapulmonary aerosol delivery of the bacterial efflux pump inhibitor MP-601,205 for CF Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Pirfenidone, proton pump inhibitor, N acetyl cysteine (PINPOINT) therapy for IPF: Tolerance and safety profile among Indian patients Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis Source: Eur Respir Monogr 2020; 88: 279-286 Year: 2020 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Biological resistance to beta-lactamic antibiotics in patients with respiratory infection in the prediction of efficiency of antibacterial therapy Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Macrolide therapy for pneumonia: balancing benefits with cardiovascular risks Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights Year: 2014 Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 The proton pump inhibitor reduces the frequency of exacerbations in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2009 - Treatment of COPD Year: 2009 Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Prevention of ventilator-associated pneumonia by selective decontamination of the digestive tract Source: Eur Respir J 2008; 32: 241-243 Year: 2008 Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021 Use of a specific risk prediction rule for the hospital management of patients with community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003 Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia Source: Eur Respir J 2009; 33: 394-400 Year: 2009